Mesothelioma

Related records

Broader conditions (7)

• Cancer or benign tumor
• Disease
• Disease by etiologic mechanism
• Human disease
• Mesothelial neoplasm
• Neoplasm
• Neoplastic disease or syndrome

Narrower conditions (31)

• Adenomatoid tumor
• Adenomatoid tumour of the peritoneum
• Benign mesothelioma
• Benign peritoneal mesothelioma
• Diffused pleural mesothelioma
• Epididymal adenomatoid tumor
• Fallopian tube adenomatoid tumor
• Localized pleural mesothelioma
• Lymphohistiocytoid mesothelioma
• Malignant biphasic mesothelioma
• Malignant epithelioid mesothelioma
• Malignant mesothelioma
• Malignant pericardial mesothelioma
• Malignant peritoneal mesothelioma
• Malignant pleural mesothelioma
• Mesothelioma of the tunica vaginalis
• Ovarian malignant mesothelioma
• Peritoneal mesothelioma
• Peritoneal mesothelioma in situ
• Peritoneal multicystic mesothelioma

Trials (294)

• 11C-Methionine PET/CT Imaging in Patients Affected by Malignant Pleural Mesothelioma (MPM)
• 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
• 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
• 18F-FSPG PET/CT for Cancer Patients on Therapy
• A 2-part Phase 1/2 Open-label Trial on ODM-212
• A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies
• A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors
• A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
• A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM
• A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy Using Extensive Pleural Resection
• A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products
• A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
• A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
• A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
• A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
• A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
• A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
• A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma
• A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy
• A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma

Approved drugs (6)

• Nivolumab
• Pemetrexed
• Pemetrexed disodium
• Pemetrexed disodium hemipentahydrate
• Pemetrexed monohydrate
• Pemetrexed tromethamine

Drugs in development (107)

• Abemaciclib Phase 2
• Acetaminophen Phase 1
• Aldesleukin Phase 1
• Amatuximab Phase 2
• Anetumab ravtansine Phase 2
• Antineoplaston A10 Phase 2
• Atezolizumab Phase 3
• Avelumab Phase 1
• Belinostat Phase 2
• Bemcentinib Phase 2
• Bevacizumab Phase 3
• Bintrafusp alfa Phase 2
• BIW-8962 Phase 1
• Bortezomib D-mannitol Phase 2
• Bosutinib Phase 1
• Cadonilimab Phase 2
• Capecitabine Phase 2
• Carboplatin Phase 3
• Catequentinib Phase 2
• Cediranib maleate Phase 2

Other linked drugs (1)

• CBP-501